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Abstract
The endothelium plays a vital role in maintaining circulatory homeostasis by the release of relaxing and contracting factors. 
Any change in this balance may result in a process known as endothelial dysfunction that leads to impaired control of vascular 
tone and contributes to the pathogenesis of some cardiovascular and endocrine/metabolic diseases. Reduced endothelium-
derived nitric oxide (NO) bioavailability and increased production of thromboxane A2, prostaglandin H2 and superoxide anion 
in conductance and resistance arteries are commonly associated with endothelial dysfunction in hypertensive, diabetic and 
obese animals, resulting in reduced endothelium-dependent vasodilatation and in increased vasoconstrictor responses. In 
addition, recent studies have demonstrated the role of enhanced overactivation of β-adrenergic receptors inducing vascular 
cytokine production and endothelial NO synthase (eNOS) uncoupling that seem to be the mechanisms underlying endothelial 
dysfunction in hypertension, heart failure and in endocrine-metabolic disorders. However, some adaptive mechanisms can 
occur in the initial stages of hypertension, such as increased NO production by eNOS. The present review focuses on the role 
of NO bioavailability, eNOS uncoupling, cyclooxygenase-derived products and pro-inflammatory factors on the endothelial 
dysfunction that occurs in hypertension, sympathetic hyperactivity, diabetes mellitus, and obesity. These are cardiovascular 
and endocrine-metabolic diseases of high incidence and mortality around the world, especially in developing countries and 
endothelial dysfunction contributes to triggering, maintenance and worsening of these pathological situations.
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Since the 1980s it has become clear that the endothelium 
is not only a monolayer that works as a physical barrier 
between blood and the underlying tissue, but also acts as 
an endocrine organ able to produce and release different 
metabolically active substances. Furchgott and Zawadzki 
(1), in 1980, showed for the first time that endothelial cells 
have an obligatory role during the relaxation induced by 
acetylcholine in isolated rabbit aorta. These investigators 
also demonstrated that acetylcholine activates muscarinic 
receptors in the endothelial cells and that this activation 
releases a substance then termed “endothelium-derived 
relaxing factor - EDRF” (1). Rapoport et al. (2) observed 
that endothelium-dependent vasodilators induce relaxation 
through cyclic GMP-dependent protein phosphorylation, 
similar to that observed with nitric oxide (NO) donors (e.g., 
sodium nitroprusside). Later, this EDRF was identified as 
NO by Ignarro et al. (3) and Palmer et al. (4). Physiologi-
cally, NO is synthesized from the amino acid L-arginine by 
the neuronal (nNOS or NOS I) and endothelial (eNOS or 
NOS III) nitric oxide synthase (NOS) enzymes. These iso-
forms are expressed constitutively and the active enzyme 
is part of a multi-protein complex forming the NOS dimer. 
The NOS dimer consists of an N-terminal oxygenase 
domain that contains binding sites for heme, L-arginine 
and tetrahydrobiopterin (BH4), and a reductase domain 
with binding sites for nicotinamide adenine dinucleotide 
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phosphate (NADPH), flavin mononucleotide (FMN), flavin 
adenine dinucleotide (FAD), and calmodulin (CaM). Upon 
activation, the oxidase domain of the NOS isoforms produces 
NO from L-arginine using O2, requiring BH4, NADPH, FMN, 
and FAD as co-factors that maintain the NOS dimer structure 
and consequently the NO synthesis (5).
In addition to NO, it is well known that endothelial cells pro-
duce and release a series of metabolically active factors. Over 
the years, it has been shown that endothelium produces several 
EDRFs, as well as NO, prostacyclin (PGI2) and endothelium-
derived hyperpolarizing factors (EDHFs). Endothelium also 
releases contractile factors (EDCFs), as well as angiotensin-II, 
endothelin-1, prostaglandins such as thromboxane A2 (TxA2), 
prostaglandin H2 (PGH2) and prostaglandin F2α (PGF2α) and 
finally reactive oxygen species (ROS). Through a fine balance 
between the release of EDRFs and EDCFs, the endothelium 
plays a vital role in maintaining circulatory homeostasis. Any 
change in this balance may result in endothelial dysfunction.
Endothelial dysfunction is a pathological condition char-
acterized by an imbalance between EDRFs and EDCFs. 
This imbalance is associated with changes in the synthesis, 
bioavailability and/or action of endothelial factors and results 
in reduction of endothelium-dependent vasodilatation and/or 
in an increased response to vasoconstrictor agonists. Thus, 
endothelial dysfunction impairs vascular function in cardiovas-
cular diseases as well as in endocrine-metabolic disorders. 
Since endothelial cells produce and release many relaxing 
and contractile factors, extensive studies have analyzed the 
factors involved in endothelial dysfunction occurring in patho-
logical conditions. The present review discusses some recent 
information concerning the role of endothelial dysfunction in 
hypertension, sympathetic hyperactivity, diabetes 
mellitus, and obesity, which are cardiometabolic 
diseases of high incidence and mortality around 
the world, especially in developing countries. We 
focused on the role of NO bioavailability, eNOS 
uncoupling, cyclooxygenase (COX)-derived prod-
ucts and the role of pro-inflammatory mediators 
in these cardiometabolic diseases. 
Endothelial dysfunction in hypertension
Hypertension is a common disease that affects 
more than 40% of the adult population in developed 
countries and about 25% in emerging countries 
such as Brazil. According to the Brazilian Ministry of 
Health (6), the proportion of Brazilians diagnosed 
with hypertension increased from 21.5% in 2006 
to 24.4% in 2009. Hypertension is characterized 
as a medical condition in which blood pressure is 
chronically elevated and is of multifactorial origin. 
In this context, physiopathological mechanisms 
such as endothelial dysfunction present in the 
blood vessels might contribute to the genesis and/
or maintenance of hypertension. 
Endothelial dysfunction is a hallmark of hypertension. 
However, the mechanisms underlying endothelial dysfunction 
differ among the experimental models of hypertension and the 
vascular beds studied. Two major functional changes have been 
frequently observed in the vasculature of hypertensive animals: 
an increased sensitivity to vasoconstrictor agents and/or a 
reduced endothelium-dependent relaxation induced by shear 
stress or agonists such as acetylcholine. These changes have 
been observed in different experimental hypertension models 
such as deoxycorticosterone acetate (DOCA)-salt hypertensive 
rats (volume-dependent hypertension model), spontaneously 
hypertensive rats (SHR, a genetic model of hypertension that 
resembles the primary hypertension of humans), ouabain-
induced hypertension (an endocrine model of hypertension 
dependent on the increment of plasma ouabain levels), among 
others (7-9). As shown in Figure 1, acetylcholine-induced 
relaxation was impaired in mesenteric resistance arteries 
from DOCA-salt hypertensive rats and SHR as compared to 
control normotensive rats. These changes have also been 
observed in hypertensive patients (10). Konishi and Su (7) first 
reported that endothelium-dependent acetylcholine-induced 
relaxation is impaired in aorta from SHR. After that, studies 
have focused on elucidating the possible pathways involved 
in this abnormality. 
A decline in NO bioavailability in hypertension is one of 
the most common features of endothelial dysfunction. It can 
be triggered by reduced eNOS gene and protein expression, 
impaired eNOS phosphorylation at the serine 1177 residue, 
decreased availability of eNOS substrate or co-factors, mainly 
BH4, altered interaction between eNOS and caveolin-1, de-
creased antioxidant defense, and/or NO inactivation by ROS. 
Figure 1. Endothelium-dependent relaxation induced by acetylcholine in mes-
enteric resistance arteries from adult (3 months old) DOCA-salt hypertensive 
rats (DOCA) (A), spontaneously hypertensive rats (SHR) (B) and normotensive 
male Wistar rats (NT) (A, B). Note that the response elicited by acetylcholine in 
arteries from the DOCA and SHR groups is biphasic and induces contraction 
at high concentrations. DOCA-salt hypertension was induced in male Wistar 
rats submitted to uninephrectomy and treated for 8 weeks with DOCA (20 mg/
kg in the first week, 12 mg/kg in the second and third weeks and 6 mg/kg until 
the end of treatment, sc) and water containing 1% sodium chloride and 0.2% 
potassium chloride. The number of rats used is indicated in parentheses. Data 
are reported as means ± SEM. *P < 0.05 vs NT (two-way ANOVA; factor 1: 
hypertension; factor 2: acetylcholine).
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Previous findings have demonstrated an impaired flow-induced 
vasodilatation in skeletal muscle arterioles from SHR that was 
due to an impairment of NO-mediated relaxation (11). In addi-
tion, aorta from SHR showed impaired endothelium-dependent 
acetylcholine-induced relaxation that was associated with 
increased superoxide anion production by NADPH oxidase 
activity (12). 
Rossoni et al. (13) have investigated vascular function in 
the experimental model of ouabain-induced hypertension in 
rats. Contrary to that observed in SHR, these investigators 
demonstrated that treatment with ouabain for 5 weeks was 
followed by an increase in endothelium-dependent relaxing 
responses, which reduced the vasoconstrictor response 
to α1-adrenergic stimulation and increased the activity of 
the Na+,K+-ATPase in conductance vessels. This effect 
was mediated by an increase in NO production related to 
overexpression of eNOS and nNOS (14). These investiga-
tors hypothesized that this adjustment was a compensatory 
mechanism for the high blood pressure observed in ouabain-
treated rats. On the other hand, we also showed that chronic 
ouabain treatment for 5 weeks increased the expression 
of pre-pro-endothelin (endothelin-1 precursor) and ETA 
receptor mRNA (15). Furthermore, chronic treatment with 
BMS182874, an ETA receptor antagonist, and losartan, an 
angiotensin-II type-1 (AT1) receptor antagonist, prevented 
ouabain-induced hypertension. Interestingly, only BMS 
182874 was able to reduce the protein expression of eNOS 
in the aorta to control levels (15), suggesting that endothelin-1 
underlies both hypertension and nitrergic aortic compensatory 
adjustment in chronic ouabain-treated rats.
Vascular changes induced by chronic ouabain treatment 
seems to be time- and vascular bed-dependent (9,16). Thus, 
5 and 10 weeks of ouabain treatment did not modify the 
noradrenaline-induced contraction in mesenteric resistance 
arteries (9,16) while 20 weeks of treatment with this gly-
coside significantly enhanced the contractile response (9). 
This effect was correlated with a decline in NO modulation 
(9) (Figure 2). In addition, we also demonstrated that the 
Figure 2. Schematic presentation of the effects elicited by α-adrenoceptor activation in endothelial (EC) and vascular smooth muscle 
cells (SMC) of small arteries from Wistar rats and spontaneously hypertensive rats (SHR) chronically treated with ouabain. AA = Arachi-
donic acid; COX-2 = cyclooxygenase-2; EDHF = endothelium-derived hyperpolarizing factor; NO = nitric oxide; NOR = noradrenaline; 
NOS = nitric oxide synthase; O2-· = superoxide anion; PGH2 = prostaglandin H2; PGs = prostaglandins; PHE = phenylephrine; sGC = 
soluble guanylate cyclase; TxA2 = thromboxane A2. ! = increase; 
!
 = decrease; Z = production and/or stimulation;  = inhibition.
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treatment of SHR with ouabain for 5 weeks exacerbates 
the hypertension of SHR associated with a decrease in NO 
modulation on small arteries (8) (Figure 2).
Previous findings have demonstrated that impaired NO 
modulation from DOCA-salt, SHR and ouabain-induced 
hypertensive rats was not only due to its reduced produc-
tion. Accelerated degradation by superoxide anion is also 
observed in these experimental models. In this respect, 
it has been shown that impaired endothelium-dependent 
relaxation observed in aorta from DOCA-salt-treated rats 
was improved by treatment with heparin-binding superoxide 
dismutase (SOD), a recombinant form of SOD that accu-
mulates in the vascular extracellular matrix and potently 
scavenges superoxide produced by vascular cells (17). 
Furthermore, removal of the endothelium significantly 
reduced superoxide levels in DOCA-salt rats but had no 
effect in normotensive rats, suggesting that high superoxide 
production in hypertensive vessels is mainly derived from 
the endothelium (17). Also, in mesenteric resistance arteries 
from rats treated with ouabain for 20 weeks, the incubation 
with SOD restored the enhanced noradrenaline-induced 
contraction (9), showing the involvement of ROS in this 
model of hypertension.
NADPH oxidase has been suggested to be the most 
important superoxide anion source in the vascular wall of 
DOCA-salt and SHR rats (12,18). Additionally, xanthine 
oxidase and mitochondria also contribute to vascular 
superoxide anion generation in hypertensive rats (18). 
Furthermore, recently our group have published that in 
mesenteric resistance arteries from ouabain-induced hy-
pertensive rats, COX-2 is the main source of superoxide 
anion generation (9) (Figure 2). 
There is evidence that persisting oxidative stress would 
render eNOS uncoupling such that it would no longer 
produce NO, but superoxide anion (19). This situation 
characterizes eNOS uncoupling when there is a stoichio-
metric mismatch between eNOS protein levels and NO 
production. Thus, superoxide anion is generated from the 
dissociation of the heme ferrous-dioxygen complex in the 
oxygenase domain of eNOS. The coupling of BH4 to L-
arginine inhibits this production of superoxide anion since 
BH4 maintains eNOS dimerization and transfers electrons 
during L-arginine oxidation (19). In agreement with this, 
in DOCA-salt hypertensive rats, the loss of BH4 induces 
eNOS uncoupling, resulting in reduced NO and increased 
superoxide anion production by this enzyme (20). In this 
context, NADPH oxidase can further contribute to oxidant 
stress not only by producing superoxide anion, but also by 
initiating BH4 oxidation. Oxidative stress may also impair the 
dimethylarginine dimethylaminohydrolase (DDAH) activity, 
resulting in increasing levels of asymmetric dimethylargi-
nine (ADMA), an eNOS endogenous inhibitor. In addition, 
ADMA contributes to eNOS uncoupling and reduces NO 
production in hypertension (19).
Endothelial dysfunction has also been associated with 
the endothelial release of vasoconstrictor substances. Ac-
cordingly, in vascular smooth muscle from hypertensive 
animals there is an increase in EDCF-mediated signaling, 
mostly prostanoids, which play an important role in en-
dothelial dysfunction. The first study suggesting the role 
of COX and its products in the endothelial dysfunction of 
SHR was published years after the discovery of the role of 
the endothelium in the control of vascular tone (21). This 
study demonstrated that acetylcholine elicited a biphasic 
response in aorta from SHR: relaxation at the lowest con-
centrations (3 to 100 nM) and a contractile response at the 
highest concentrations (300 nM to 10 µM) of this agonist. It 
is important to emphasize that this response is also seen 
in mesenteric resistance arteries from SHR (Figure 1B). 
In line with the investigation of the mechanisms involved 
in this biphasic response, studies demonstrated that the 
contraction induced by acetylcholine was abolished by 
indomethacin, a COX-1/2 inhibitor, and by TxA2/PGH2 (TP) 
receptor blockers in both aorta and resistance arteries from 
SHR (22,23). 
Studies have shown that the constitutive COX isoform 
(COX-1) is the main factor responsible for the acetylcholine-
induced contractile response in aorta from SHR (21), since 
a specific inhibitor of COX-1 (SC-560), but not COX-2 
(NS-398), was able to abolish this contraction. However, 
other studies have demonstrated that COX-2-derived 
prostanoids play a fundamental role in the endothelial dys-
function observed in DOCA-salt and ouabain-hypertensive 
rats (8,9,24).
Recently, we have shown that both indomethacin (a 
COX-1/2 inhibitor) and NS-398 (a selective COX-2 inhibitor) 
reduced the hyperreactivity to noradrenaline in mesenteric 
resistance arteries from rats with 20-week ouabain-induced 
hypertension (9). These functional changes were followed 
by an increase of COX-2 protein expression in mesenteric 
resistance arteries from ouabain-treated rats (9). Further-
more, incubation with ridogrel (a TxA2 synthase inhibitor and 
PGH2/TxA2 receptor antagonist) decreased the contractile 
response to noradrenaline in resistance arteries from rats 
treated with ouabain for 20 weeks, suggesting that TxA2 
and/or PGH2 are the major vasoconstrictor prostanoids 
stimulated by noradrenaline in this hypertension model 
(Figure 2). Consistent with these results, the tail artery from 
SHR treated with ouabain for 5 weeks showed enhanced 
phenylephrine-induced contraction that was associated 
with TxA2 and/or PGH2 derived from COX-2 metabolism 
(8) (Figure 2).
The aforementioned studies suggest the involvement 
of oxidative stress, COX-derived products, and/or reduced 
NO bioavailability in endothelial dysfunction in hyperten-
sion. Treatment with antioxidant vitamins, NADPH oxidase 
inhibitors, SOD mimetics, BH4, or AT1 receptor blockers de-
creases superoxide anion production, improves endothelial 
function and attenuates the development of hypertension 
(18). Taken together, these lines of experimental evidence 
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(18) underscore the complexity of the interactions among 
NO, oxidative stress and endothelial dysfunction in hyper-
tension. In addition, our group demonstrated that ouabain, 
besides inducing oxidative stress and COX-2-derived pros-
tanoid production, increases the release of proinflammatory 
cytokines in the arteries (8,9). Thus, it may be possible that 
treatment with anti-inflammatory drugs and/or inhibitors 
of ouabain action could become a strategy to reduce the 
vascular damage in refractory hypertension. 
Endothelial dysfunction and sympathetic 
hyperactivity 
Sympathetic hyperactivity is a common feature of car-
diovascular diseases and is a relevant predictor of mortality 
rate in patients with heart failure (25). In heart failure, the 
increased sympathetic outflow contributes to vasocon-
striction and, consequently, to the increment of systemic 
vascular resistance leading to increased afterload. Elevated 
afterload further increases cardiac workload and worsens 
the symptoms of heart failure.
The alterations in vascular tone occurring in heart 
failure have been linked to endothelial dysfunction. In 
agreement with this, impairment of endothelium-dependent 
vasodilatation was demonstrated in heart failure patients, 
as demonstrated by measurements of forearm blood 
flow responses to acetylcholine (26). These authors also 
observed that the blunted vasodilatation in response to 
acetylcholine was significantly improved by intra-arterial 
infusion of phentolamine, an α1-adrenoceptor antagonist 
(26). Therefore, an enhanced vascular sympathetic nerve 
activity could restrain endothelium-mediated vasodilatation 
in chronic heart failure patients. 
Experimentally, coronary artery ligation in rats has been 
used extensively as a model of chronic left ventricular failure. 
Using this experimental model, most studies observed an 
impairment of endothelium-dependent relaxation (27,28). 
Temporal analysis of endothelial function in aortic rings 
from myocardial infarcted rats showed that there was no 
evidence of impaired acetylcholine-induced relaxation after 
1 week of coronary artery ligation, with the effect becom-
ing evident only at 4 weeks after myocardial infarction and 
progressively worsening until week 16 (27). This clearly 
indicates that endothelial dysfunction in heart failure may 
depend on its stage with time.
An imbalance between NO and superoxide anion 
production leading to enhanced NO inactivation has been 
associated with endothelial dysfunction in heart failure and 
appears to be a common feature of many cardiovascular 
diseases associated with sympathetic hyperactivity (28). 
Heart failure patients and rats after myocardial infarction 
show elevated plasma norepinephrine levels. However, the 
myocardial infarction caused by coronary artery ligation, 
in addition to inducing sympathetic overflow, also induces 
important humoral changes, including activation of the 
renin-angiotensin-aldosterone system (29,30). Activation 
of plasma and/or tissue renin-angiotensin-aldosterone 
system plays a key role in vascular dysfunction in heart 
failure. In this respect, it was demonstrated that angiotensin-
converting enzyme (ACE) inhibitors, AT1 receptor blockade 
and mineralocorticoid receptor antagonists could improve 
the endothelial dysfunction observed in rats after myocardial 
infarction (29,30). These beneficial effects of blockade of 
the renin-angiotensin-aldosterone system on endothelial 
function were accompanied by decreased superoxide anion 
generation and they are at least part of the mechanism as-
sociated with improvement of vasomotor function in heart 
failure animals (29,30). 
Cardiovascular effects of sympathetic overflow can 
also be mimicked by sustained infusion of low doses of 
catecholamine, with the activation of adrenoceptors be-
ing, in this case, the first signaling event. Moreover, it is 
known that β-adrenergic stimulation could activate the 
renin-angiotensin-aldosterone system. The administration 
of isoproterenol, a non-selective β-adrenoceptor agonist, 
to laboratory animals for several days is used as a model 
of prolonged β-adrenoceptor stimulation. In the vascula-
ture of these animals, we demonstrated that isoproterenol 
treatment increases the vasoconstrictor response to the 
α1-adrenoceptor agonist phenylephrine as well as to the 
serotonin (5-HT) agonist in rat (31) and mouse (Figure 3A) 
aorta, although no changes in acetylcholine-induced relax-
ation were observed (31,32). In addition, endothelial removal 
and L-NAME incubation normalized the hyperreactivity to 
phenylephrine observed in aortas from isoproterenol-treated 
rats, indicating that persistent activation of β-adrenoceptors 
impairs basal endothelial-derived NO (31,32). The reduction 
of basal NO availability induced by isoproterenol was not 
related to a reduction in eNOS activity. Indeed, eNOS activity 
and protein expression were found to be significantly en-
hanced in aortas from isoproterenol-treated rats (31). How-
ever, chronic isoproterenol treatment enhanced superoxide 
anion levels, measured by hydroethydine fluorescence 
in situ in rat (31) and mouse aorta (Figure 3B). Thus, an 
exacerbated inactivation of basal NO by superoxide anion 
can be responsible for the increased constrictor reactivity 
of aortas induced by chronic treatment with isoproterenol. 
Accordingly, incubation of aortic rings with SOD restored 
the responsiveness to phenylephrine in rat (31) and mouse 
aorta from isoproterenol-treated animals (Figure 3A).
The maladaptive effects of chronic activation of 
β-adrenoceptors were unexpected, since it is known that 
acute administration of β-adrenoceptor agonists, including 
isoproterenol, induces vasorelaxation by activation of an 
adenylyl cyclase-cAMP-PKA pathway, that causes hyperpo-
larization and decreases the sensitivity of myofilaments to 
Ca2+. In addition, activation of β-adrenoceptors on the en-
dothelium stimulates synthesis of NO by eNOS (33) (Figure 
4). However, it has been demonstrated that overexpression 
of eNOS could paradoxically be maladaptive by leading 
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to oxidative stress through synthesis of superoxide anion 
(19). In agreement with this hypothesis, we demonstrated 
that aortas from isoproterenol-treated animals present an 
increased activity and protein expression of eNOS and 
nNOS; in addition, L-arginine supplementation was able to 
normalize the hyperreactivity to phenylephrine (31). Thus, 
sustained β-adrenoceptor activation could exacerbate 
eNOS activity and expression, but, in turn, cause eNOS 
uncoupling that would become a source of superoxide anion 
production (Figure 4). In addition, aortas from rats with heart 
failure induced by coronary artery ligation show increased 
eNOS mRNA and protein expression associated with high 
superoxide anion levels (28). It is noteworthy that other 
sources of superoxide anion generation such as NADPH 
oxidase and xanthine oxidase have been suggested to be 
activated in blood vessels from rats and patients with heart 
failure (28,29).
It has been proposed that, in association with oxida-
tive stress, an increased production of cytokines and 
other mediators of inflammation has a pathological role 
in generating and/or worsening endothelial dysfunction in 
many cardiovascular diseases. It is known that cytokines 
such as interleukin (IL)-1β could impair the endothelium-
dependent relaxation in resistance arteries (34). We previ-
ously demonstrated that isoproterenol treatment for 7 days 
significantly enhanced mRNA and protein expression of 
IL-1β and IL-6 and the activity of the nuclear factor kappa B 
(NF-κB) in aortic homogenates (35). Interestingly, suppres-
sion of NF-κB activity via oral treatment with thalidomide 
improved the hyperreactivity to phenylephrine observed 
in isoproterenol-treated rats (35). Thus, anti-inflammatory 
drugs emerge as a therapeutic approach to treat endothe-
lial disorders in cardiovascular diseases associated with 
sympathetic overflow. 
Therefore, there is convincing evidence suggesting that 
reduced NO bioavailability following sympathetic hyperac-
tivity and/or increased plasma catecholamine levels is the 
major contributor to endothelial dysfunction. Generation of 
superoxide anion by uncoupled eNOS and inflammatory 
mediator synthesis induced by chronic β-adrenergic activa-
Figure 3. Effect of 7-day isoproterenol treatment on vascular function and superoxide generation in mouse aorta. A, Contraction 
response to phenylephrine in aortas with endothelium from control (CT) and isoproterenol (ISO)-treated FVB mice. Superoxide dis-
mutase (SOD) incubation (150 U/mL; 30 min) restored the contractile response to phenylephrine of isoproterenol-treated rats. Data 
are reported as a percentage of the response to 75 mM KCl in each aortic ring. Data are reported as means ± SEM. *P < 0.05 ISO vs 
CT; #P < 0.05 ISO vs ISO/SOD (two-way ANOVA). B, Representative fluorescence photomicrographs of slices of aorta from CT and 
ISO-treated FVB mice. Vessels were labeled with the oxidative dye hydroethidine, which produces a red fluorescence when oxidized 
to ethidium bromide by superoxide anion.
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tion seem to play a central role in the endothelial dysfunction 
induced by sympathetic overflow. Thus, both mechanisms 
may be therapeutic targets for cardiovascular diseases 
associated with endothelial dysfunction and sympathetic 
hyperactivity.
Endothelial dysfunction in diabetes 
mellitus
Diabetes mellitus (DM) is currently considered to be the 
major epidemic of the century and a public health problem 
worldwide. In the 1980s it was estimated that 30 million 
individuals had DM worldwide. This number increased 
to 135 million in 1995, reaching 173 million in 2002, and 
300 million people have been predicted to develop DM 
by 2030 (36). Approximately two-thirds of these patients 
live in developing countries, where the epidemic is most 
intense, with increasing proportions of affected individuals 
among younger age groups. DM has been associated 
with high mortality and a high incidence of cardiovascular 
complications, which account for about 70% of all deaths in 
patients with DM. The incidence, prevalence and mortality 
of cardiovascular disease, such as myocardial infarction, 
stroke, hypertension, atherosclerosis, and heart failure are 
approximately 3-5 times higher among diabetic than non-
diabetic subjects (36).
Alterations in vascular function are considered to be fac-
tors closely related to the development and/or maintenance 
of cardiovascular complications in patients with DM and may 
occur even in the early stages of the disease. Although the 
nature of the pathogenic link between elevated circulating 
levels of glucose and cardiovascular complications is a 
source of debate, it is clearly recognized that hyperglycemia 
is responsible for the pathogenesis of vascular complica-
Figure 4. Schematic presentation of the effect of acute and chronic β-adrenergic activation on endothelial nitric oxide synthase (eNOS) 
activity, expression and uncoupling. A, In normal vessels, basal eNOS activity oxidizes L-arginine, producing L-citrulline and nitric oxide 
(NO) at physiological rates, contributing to vascular tone maintenance. B, Acute β-adrenergic activation induced by β-adrenoceptor 
agonists induces eNOS activity and could increased endothelial NO release. C, Sustained elevated catecholamine levels could induce 
overactivation of β-adrenoceptors that enhance activity and protein expression of eNOS but, in turn, eNOS becomes uncoupled, gen-
erating superoxide anion (O2-·).
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tions associated with DM. It has been demonstrated that 
acute or chronic hyperglycemia can cause several changes 
in vascular function, including a decrease in endothelium-
dependent relaxation (37-39), an increased contractile 
response of vascular smooth muscle (38,40,41) and a pre-
disposition to the development of inflammatory, thrombotic 
and atherosclerotic events (42).
The progression of vascular disease in DM is largely 
related to endothelial dysfunction mechanisms. Impaired 
endothelium-dependent vasodilatation has been demon-
strated in various vascular beds of different animal models 
of DM and in human patients with types 1 and 2 DM (37-39). 
Under these conditions there is vasoconstriction, increased 
adhesion of platelets and leukocytes, an uncontrolled growth 
of cells, especially smooth muscle in the vessel wall, an 
increase in lipids depots in the subendothelium, and an 
increased tendency to develop vascular thrombosis. The 
mechanisms associated with these events may be multiple 
and include changes in synthesis, release, diffusion, or deg-
radation of various factors produced by endothelial cells. In 
DM, endothelial dysfunction is not a homogeneous process 
in its characteristics and distribution, but it varies depending 
on the duration of the exposure to hyperglycemia and on 
the vascular bed evaluated (37,41). Several mechanisms 
have been proposed to explain the endothelial functional 
abnormalities associated with the exposure of the vascu-
lar tissue to hyperglycemia. The increased activity of the 
polyol pathway, nonenzymatic glycation of proteins with 
the production of advanced glycation endproducts (AGEs), 
oxidative stress, with an increase in ROS production, and 
alterations in protein kinase C (PKC) are mentioned in the 
literature as the main mechanisms involved in endothelial 
dysfunction and atherogenesis, preceding the above-men-
tioned vascular complications in patients with DM.
The most notable characteristic of endothelial dysfunc-
tion associated with DM is the vascular NO reduction. Mul-
tiple mechanisms are involved in this effect, but increased 
oxidative stress seems to be the first alteration that triggers 
several others. The importance of oxidative stress in me-
diating the vascular complications of DM is supported by 
studies showing that antioxidants such as vitamin C and 
E or SOD correct the endothelium-dependent vasodilator 
function in humans, in experimental models of DM or in ar-
teries exposed to high glucose (42). Hyperglycemia induces 
oxidative stress by increasing superoxide anion production 
by the mitochondrial electron transport chain and activation 
of NADPH-dependent oxidases (42). 
In the presence of hyperglycemia, the increased su-
peroxide production leads to formation of peroxinitrites 
(ONOO-), which may react with the co-factor for NOS, BH4, 
leading to its degradation. In diabetic rats, reduced levels of 
BH4 have been reported. According to these results, BH4 
supplementation to diabetic rats improves the endothelium-
dependent relaxation, suggesting that uncoupled eNOS 
plays a role in diabetic endothelial dysfunction (39). As 
previously described, oxidative stress may also impair 
DDAH activity, resulting in increasing levels of ADMA. These 
results therefore suggest that, in addition to its increased 
degradation, NO synthesis may be decreased by vascular 
tissue exposure to hyperglycemia.
The sensitivity of vascular smooth muscle may be re-
duced even with an adequate supply of NO. Vascular studies 
in humans and in animal models of DM have commonly 
used NO donors or nitrovasodilators (e.g., sodium nitroprus-
side) as a control for the study of endothelium-dependent 
vasodilatation. These agents act directly on vascular smooth 
muscle resulting in an endothelium-independent vasodila-
tion. Evidence suggests that the vascular smooth muscle 
sensitivity to NO is reduced in diabetes and in arteries 
exposed to hyperglycemia in vitro, indicating that hypergly-
cemia interferes with the activation of guanylate cyclase by 
NO (43). On the other hand, other studies have suggested 
increased production of NO, or increased sensitivity of 
vascular smooth muscle cells to NO, in diabetes.
As described above, endothelial dysfunction could also 
be related to the release of vasoconstrictor substances. In 
vessels of diabetics there is an increase in endothelium-
dependent vasoconstrictor mechanisms, mostly mediated 
by prostanoids, which play an important role in endothelial 
dysfunction. For example, in mesenteric and coronary 
arteries from diabetic dogs, exogenous arachidonic acid 
induces TxA2-mediated contraction. In contrast, arachidonic 
acid leads to PGI2-mediated relaxation in the arteries of 
controls (44). Additionally, a reduction in the relaxation 
induced by acetylcholine in diabetic aortas, mesenteric 
and femoral arteries is corrected by COX inhibitors (45). 
An increased participation of vasoconstrictor prostanoids 
in the arteries of diabetic rats, such as TxA2 and PGF2α 
has also been reported (41,46). Thus, TP receptor antago-
nism can restore the impaired relaxation and prevent the 
endothelium-dependent contraction in arteries exposed to 
hyperglycemia (41,46). TxA2 plays a role not only in the 
reduction of endothelial function in type 1 DM, but may 
also be involved in the enhanced contractile response to 
vasoconstrictor agents (41).
Hyperglycemia selectively increases the expression 
of COX-2 without affecting COX-1 levels, leading to in-
creased release of vasoconstrictor prostanoids (45). The 
mechanisms by which hyperglycemia leads to COX-2 over-
expression are not clear. However, accumulating evidence 
indicates that ROS activates specific redox-sensitive signal 
transduction pathways and transcriptional regulatory events 
that increase COX-2 expression in the vascular wall (45). In 
support of this view, it has been reported that, under high 
exposure to glucose, endothelial cells increase the produc-
tion of superoxide anion, which was primarily responsible 
for the enhanced COX-2 expression (47). Hyperglycemia 
not only modifies the profile of prostanoids, leading to al-
teration of vasomotor tone, but also increases the release 
of arachidonic acid by vascular cells (46). 
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It has been shown that the concentration of diacylglyc-
erol (DAG) in hyperglycemia is elevated in vascular cells 
and tissues. It increases through the acylation of triose 
intermediates generated by glycolysis, which leads to the 
synthesis of fatty acids and subsequent acylation of glycerol. 
DAG is a co-factor, which is rate limiting for PKC (48). PKC 
and phospholipids generated by calcium-activated phospho-
lipase A2 (cPLA2) regulate several vascular functions such 
as cell growth, permeability, contractility, and extracellular 
matrix protein synthesis. In diabetes, activation of PKC 
induces an increase in vascular smooth muscle contractility 
(40) and expression of NADPH oxidase, resulting in ROS 
generation (42) and decreased Na+,K+-ATPase activity (49). 
However, we have recently reported that diabetic aorta is 
also associated with increased Na+,K+-ATPase activity, an 
effect, which is also mediated by PKC (50). In these arteries, 
TxA2/PGH2 released by COX-2 activates PKC βII, which in 
turn increases Na+,K+-ATPase activity (Figure 5). This is 
possibly a counter-regulatory mechanism to the vascular 
dysfunction present in this artery.
Hyperglycemia is also associated with increased pro-
duction of AGEs that play a role in endothelial dysfunction 
associated with DM. Through activation of their receptor, 
AGEs increase production of ROS via NADPH oxidase (51). 
Activation of these receptors, when linked to monocytes/
macrophages, also initiates important processes for tis-
sue remodeling. The cellular connection of AGE proteins 
induces cellular responses such as enhanced production of 
cytokines, growth factors, laminin, fibronectin, and collagen 
type IV in mesangial cells via PDGF synthesis, as well as 
increased angiogenesis in endothelial cells. Hyperglycemia 
can lead to sorbitol accumulation via aldose reductase and 
Figure 5. Schematic presentation of the proposed signal transduction pathway involved in altered Na+,K+-ATPase activity induced by 
type I diabetes in aorta. The model shows vascular smooth muscle cell (SMC) containing the catalytic α-isoform of Na+,K+-ATPase 
(NKA) and the abolished effect of endothelium-derived nitric oxide (NO) on this enzyme. Increased protein levels of cyclooxygenase-2 
(COX-2) in SMC elevated prostanoid (TxA2 and PGH2) synthesis and their autocrine activity via TxA2/PGH2 receptor enhances the 
phosphorylated βII isoform of PKC (p-PKC βII), which increases vascular contractility but in turn activates NKA. EC = Endothelial cell; 
DAG = diacylglycerol; IP3 = inositol trisphosphate; PIP2 = phosphatidylinositol 4,5-bisphosphate. ! = increase; 
!
 = decrease; Z = 
production and/or stimulation; dotted white line with arrow pointing downwards = inhibition.
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sorbitol can be converted into fructose by sorbitol dehydro-
genase. This increased flow causes elevation of osmotic 
pressure, decreases the myoinositol concentration and, 
together with glycolysis, changes the intracellular redox 
balance. 
Therefore, understanding the physiological mechanisms 
involved in vascular disorders resulting from hyperglyce-
mia is essential for the proper use of available therapeutic 
resources. 
Obesity and endothelial dysfunction
The prevalence of obesity is on the rise and has reached 
epidemic proportions. Obesity is characterized by exces-
sive fat accumulation that may impair health. In fact, the 
excessive accumulation of adipose tissue in the upper body, 
so-called central or visceral obesity, has a major role in the 
development of obesity-related metabolic and cardiovascu-
lar disorders, such as insulin resistance, impaired glucose 
tolerance, dyslipidemia, and elevated blood pressure (52). 
Therefore, risk factors for cardiovascular disease coexist in 
obese people and the installation of these diseases begins 
when the risk factors induce endothelial dysfunction.
Despite the fact that obesity-related disorders can 
individually impair endothelial function, visceral adiposity 
also affects endothelial function. The severity of endothelial 
dysfunction correlates with the degree of visceral adiposity 
(52). Adipocytes and adipose tissue-derived macrophages 
secrete several factors capable of directly affecting endothe-
lial function. Such factors are called adipokines, and com-
prise cytokines, chemokines, and hormone-like proteins, 
such as tumor necrosis factor-alpha (TNF-α), IL-6, leptin, 
angiotensin-II, plasminogen activator inhibitor-1, resistin, 
and monocyte chemoattractant protein-1 (52). Uncontrolled 
secretion of adipokines by obese hypertrophic adipocytes 
promotes a systemic inflammatory state, which contributes 
to cardiovascular diseases. 
Besides visceral adipose tissue, increased fat depots 
around blood vessels also contribute to endothelial dys-
function. Perivascular adipose tissue has been shown to 
release vasodilator and vasoconstrictor factors and also a 
variety of adipokines (53). Although during initial steps of 
diet-induced obesity perivascular adipose tissue-derived 
leptin induces an adaptive NO overproduction, contributing 
to preserving vascular function, obese perivascular adipose 
tissue-derived adipokines appear to promote local inflam-
mation (53). This process, together with systemic inflam-
mation, can contribute to alterations of endothelial function. 
Moreover, we have recently demonstrated an increase in 
TNF-α protein expression directly in perivascular adipose 
tissue-cleaned aorta from mice with high-fat diet-induced 
obesity (54). Whether systemic and perivascular adipose 
tissue-induced inflammation is involved in the induction 
of TNF-α expression in vascular cells is not yet known. 
Whatever the source of inflammatory factors, however, the 
endothelium may be negatively affected by proinflamma-
tory cytokines. The exact visceral and perivascular adipose 
tissue-derived factors implicated in endothelial dysfunction 
in obesity are not known, but TNF-α and IL-6 have emerged 
as possible candidates (55). 
It has been demonstrated that cytokines impair en-
dothelial function, manifested as a reduced NO-dependent 
relaxation (34). TNF-α-induced endothelial dysfunction can 
be due to a reduced NO production by inhibition of eNOS 
gene expression in endothelial cells. Similarly to the TNF-α 
effect, reduction of eNOS expression was observed in 
aorta from mice with high-fat diet-induced obesity, which 
exhibit increased inflammatory markers (54). Obesity 
modifies post-translational eNOS regulation that results 
also in reduced NO production. Reduced eNOS phos-
phorylation (ser 1177) via phosphatidylinositol 3-kinase/
Akt (56) and uncoupled eNOS (57) are related to impaired 
endothelium-dependent relaxation in obesity. Moreover, 
protein expression of caveolin-1, which inhibits eNOS ac-
tivity in endothelial cells via protein-protein interactions, is 
increased in aorta from rats with diet-induced obesity (58). 
Thus, a reduced NO production is involved in the impaired 
endothelium-dependent relaxation in obese animals, but 
how obesity modifies transcriptional and post-translational 
eNOS regulation is still unclear. 
Proinflammatory cytokines not only reduce NO produc-
tion, but also decrease its bioavailability due to increased 
ROS bioavailability. Several sources of ROS, such as 
NADPH oxidase, xanthine oxidase, uncoupled eNOS, 
and mitochondrial respiratory chain, can be stimulated by 
proinflammatory cytokines in endothelial cells (52). It is well 
established that oxidative stress is implicated in endothelial 
dysfunction in the obese condition. Incubation with com-
pounds that quench ROS, such as SOD and tiron, restores 
the reduced endothelium-dependent relaxation in arteries 
of obese animals (54,57). Although increased vascular 
cell-produced ROS can be observed in arteries of obese 
animals (57), obese perivascular adipose tissue-derived 
ROS can have a paracrine action on the vascular wall and 
impair the endothelium-dependent relaxation (53). Obesity 
can also impair the vascular antioxidant capacity. We have 
demonstrated a decrease in Cu/Zn-SOD protein expres-
sion, which could contribute to a decrease in antioxidant 
capacity and consequently superoxide anion accumulation 
in the aorta from mice with high-fat-induced obesity (54). 
Therefore, increase in ROS levels, together with reduced 
NO production, represent at least part of the mechanism 
underlying endothelial dysfunction in obesity.
In addition to reducing NO bioavailability, increased ROS 
levels can also promote inflammation. The NF-κB family 
members are important redox-sensitive transcriptional fac-
tors that regulate transcription of genes that encode inflam-
matory cytokines, adhesion molecules, chemokines, iNOS, 
and COX-2 (55). In turn, many products of NF-κB-regulated 
genes activate NF-κB, which exacerbates the inflammatory 
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status by producing ROS and additional cytokines, worsen-
ing the pathological processes and leading to endothelial 
dysfunction. Many of these products of NF-κB activation 
impact the endothelium-dependent relaxation, such as 
TNF-α, as described earlier, and the enzyme COX-2 (55). 
Indeed, an increase in COX-2 protein expression is observed 
in arteries from obese rats, which contributes to reduced 
endothelium-dependent vasodilation (57,59). Thus, inhibi-
tion of NF-κB may be able to restore the obesity-induced 
endothelial dysfunction. 
The NF-κB pathway appears to be up-regulated in 
vascular cells from obese individuals. Endothelial cells from 
obese humans presented elevated NF-κB expression when 
compared to lean adults (60). Moreover, we have observed 
a reduction in IκB protein expression in the aorta from obese 
mice (54). Although NF-κB is thought to play a role in me-
diating endothelial dysfunction in obesity, there are a few 
studies showing direct evidence of NF-κB contribution to this 
condition. Oral administration of salsalate (nonacetylated 
salicylate) for 4 days inhibits NF-κB in venous endothelial 
cells and improves flow-mediated endothelium-dependent 
relaxation in the brachial artery of non-diabetic overweight/
obese middle-aged humans (60). Moreover, inhibition of 
NF-κB also reduces adipocyte-induced adhesion mol-
ecule expression in human umbilical venous endothelial 
cells. Similarly, we have demonstrated a correction of the 
reduced endothelium-dependent relaxation in obese mice 
by incubating aortic rings with salicylate (54). This finding 
suggests the direct participation of the NF-κB pathway in 
the impaired endothelium-dependent relaxation in obese 
mice. Taken together, data from these studies demonstrate 
the direct participation of the up-regulated NF-κB pathway in 
vascular cells from obese subjects, which could contribute 
to vascular inflammation and endothelial dysfunction. 
The specific mechanism by which inhibition of vascular 
NF-κB restores endothelial dysfunction in obesity is also not 
clear. In endothelial cells, NF-κB activation is associated with 
an increase in NADPH oxidase-derived superoxide levels. 
Since both inhibition of NF-κB activity and antioxidant com-
pounds showed similar effects on endothelium-dependent 
vasodilation (54,60), inhibition of NF-κB might improve 
endothelial function by reducing ROS levels. However, 
the sequence of events leading to endothelial dysfunction 
still needs to be elucidated, including the possibilities that 
NF-κB could increase ROS availability or that ROS could 
activate NF-κB. 
It is clear that systemic and local inflammation associated 
with oxidative stress is implicated in endothelial dysfunc-
tion in obesity. Many pharmacotherapies (e.g., glitazones, 
fibrates, metformin, and statins) and even weight loss, which 
have a cardioprotective effect, reduce systemic inflamma-
tion, at least in part by inhibiting inflammatory signaling 
in adipocytes. A direct effect of vascular NF-κB activation 
appears to make an important contribution to this condition, 
which may be partially mediated by oxidative stress. Addi-
tional studies aimed at elucidating specific mechanisms of 
endothelial function impairment by NF-κB would most likely 
support vascular NF-κB as a crucial target in a therapeutic 
strategy to treat obesity-induced cardiovascular disease. 
Conclusion
In conclusion, endothelial dysfunction is a hallmark of 
most cardiovascular and endocrine/metabolic diseases. It 
is induced by complex changes in the balance between 
EDRF and EDCF production, bioavailability and action in 
smooth muscle cells. Reduction of NO bioavailability due to 
impaired NO synthesis by eNOS, increased oxidative stress 
and eNOS uncoupling are common mechanisms underly-
ing endothelial dysfunction in many cardiovascular and 
endocrine diseases. In addition, COX-2-derived prostanoids 
and pro-inflammatory cytokines could be overproduced 
in hypertension, diabetes and obesity. Although much is 
known about the importance of endothelial dysfunction 
in the pathophysiology of cardiovascular diseases, these 
diseases still have a high mortality worldwide. Thus, further 
research of the vascular pathophysiology of cardiovascular 
diseases is needed in order to determine exact tools for a 
proper treatment in each case.
Finally, the present review reinforces the importance of 
anti-inflammatory drugs (e.g., NF-κB and COX-2 inhibitors) 
and eNOS co-factors (e.g., BH4) as an effective pharma-
cotherapy strategy to improve endothelial dysfunction 
present in classical cardiovascular diseases associated 
with sympathetic hyperactivity such as heart failure and 
hypertension, and also in endocrine/metabolic disorders 
including type I and II diabetes and obesity. In addition, 
drugs that chronically inhibit the vascular action of oua-
bain represent a strategy for reducing vascular damage in 
refractory hypertension. The potential beneficial effects of 
these drugs on endothelial function could be effective in 
improving the local control of vascular tone in worldwide 
cardiovascular and metabolic diseases. 
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